Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2Recruiting 2Suspended 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 30Neoplasm Metastasis 17Skin Neoplasms 9Leukemia, Myeloid, Acute 8Neoplasms 7Kidney Neoplasms 7Ovarian Neoplasms 6Carcinoma, Renal Cell 6Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Neuroblastoma 4Lymphoma, Non-Hodgkin 4Leukemia 4Breast Neoplasms 4Lymphoma 3Lung Neoplasms 3Congenital Abnormalities 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 2Triple Negative Breast Neoplasms 2Sezary Syndrome 2Rectal Neoplasms 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2

Interventions

pembrolizumab 20Carboplatin 14Cyclophosphamide 12atezolizumab 11Paclitaxel 10Albumin-Bound Paclitaxel 8Capecitabine 7Nivolumab 6130-nm albumin-bound paclitaxel 6spartalizumab 5fludarabine 5Taxes 5Gemcitabine 5talazoparib 4bintrafusp alfa protein, human 4avelumab 4Cisplatin 4sacituzumab govitecan 3olaparib 3entinostat 3Leucovorin 3Ipilimumab 3Immunoglobulin G 3Drug Therapy 3Doxorubicin 3Docetaxel 3Biopsy 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3trilaciclib 2eribulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Triple Negative Breast Neoplasms × aldesleukin × Clear all
NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
36 enrolled 7 charts
Breast

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04551885 2023-09-21

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
12 enrolled
BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡